Introduction
Grepafloxacin (OPC-17116) is a new orally active fluoroquinolone with enhanced activity against Gram-positive cocci, whilst preserving good activity against Gramnegative organisms, including Haemophilus influenzae and Moraxella catarrhalis. [1] [2] [3] [4] The antibiotic also has excellent in-vitro activity against Neisseria gonorrhoeae. 5 The use of quinolones for the treatment of respiratory and genital infections is now well established. Pharmacokinetic and tissue penetration studies indicate that grepafloxacin reaches high intracellular levels, which are maintained for 10-12 h after a single oral dose. 6 There is therefore considerable potential for the use of oral grepafloxacin in respiratory and genital infection, with a once-or twice-daily treatment regimen. The activity of grepafloxacin against intracellular organisms associated with respiratory and genital infection is therefore of particular interest. This study was undertaken to investigate the in-vitro activity of grepafloxacin compared with that of ofloxacin, clarithromycin and doxycycline against organisms associated with so-called atypical pneumonia, and related organisms: Chlamydia pneumoniae, Chlamydia trachomatis, Mycoplasma pneumoniae, Mycoplasma hominis, Ureaplasma urealyticum and Legionella spp.
Materials and methods
Grepafloxacin was supplied by Glaxo-Wellcome, ofloxacin and rifampicin by Hoechst Marion Roussel, clarithromycin by Abbott Pharmaceuticals and doxycycline by Pfizer Inc.
Chlamydia spp.
MICs were determined using a tissue culture incorporation technique in McCoy cell monolayers treated with 5-iodo-2-deoxyuridine for C. trachomatis, and cycloheximide for C. pneumoniae. The method was based on that of Ridgway et al., 7 and modified for C. pneumoniae by Fenelon et al. 8 The inoculum used was approximately 3 10 4 inclusion forming units/mL. After 48-72 h incubation, cover slips were fixed in methanol and stained with an immunofluorescent monoclonal antibody against the major outer membrane protein of C. trachomatis or chlamydial genus-specific lipopolysaccharide (for C. trachomatis and C. pneumoniae, respectively). MIC end-points were determined as the lowest concentration of antimicrobial which prevented formation of recognizable intracellular inclusions after 48 h of incubation. Two strains from each species were multiply passaged in antimicrobial-free growth medium following determination of the MIC, until a stable end-point was reached. The
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MBC was designated the lowest concentration of antimicrobial present in the original culture that inhibited inclusion formation after multiple passage. 7 
Mycoplasmas
MICs for Mycoplasma spp. and Ureaplasma spp. were determined using a microbroth incorporation technique in Mycoplasma Growth Medium (Oxoid Ltd, Basingstoke, UK) supplemented to contain final concentrations of 0.1% (w/v) glucose for M. pneumoniae, 0.1% (w/v) arginine for M. hominis and 0.1% (w/v) urea for U. urealyticum, as previously described by Felmingham et al. 9 The inoculum was approximately 10 5 colour changing units and the MIC endpoints were determined as the lowest concentration of antimicrobial which prevented growth of the inoculum after appropriate incubation, as evidenced by a pH change when compared with an antimicrobial-free growth control.
Legionella spp.
MICs for Legionella spp. were determined using an agar incorporation method in supplemented buffered yeast extract medium containing water-lysed horse blood (5% v/v final concentration), as previously described by Felmingham et al. 9 The inoculum used approximately 10 4 cfu of each isolate contained in a volume of 1 L, delivered to the surface of the agar plate using a multipoint inoculator. MIC end-points were read as the lowest concentration of antimicrobial which inhibited visible surface growth after overnight incubation at 37°C for 48-72 h.
Results
The comparative activities of grepafloxacin and the other antimicrobials tested are shown in Tables I-IV . Against the chlamydiae, grepafloxacin was some 8-16 times more active than ofloxacin, showing activity similar to that of doxycycline, and equal or two-to four-fold less active than clarithromycin. As previously noted with other quinolones, 10 grepafloxacin was bactericidal at or within one dilution of the MIC. Grepafloxacin was four-fold more active than ofloxacin against M. pneumoniae and U. urealyticum, but 16 times more active against M. hominis. As previously noted for other quinolones, grepafloxacin was more active against M. hominis than against U. urealyticum. 10 In contrast, and as expected, clarithromycin had no useful activity against M. hominis, but was highly active against M. pneumoniae and U. urealyticum.
The activity of grepafloxacin was equivalent to those of ofloxacin and clarithromycin against Legionella spp. There was no apparent difference in activity against species other than L. pneumoniae but only a small number of strains was available.
Discussion
In general, our findings confirm those of others. Wise et al. 4 examined three strains of C. trachomatis, and obtained an MIC range for grepafloxacin of 0.06-0.25 mg/L. They also examined the TW183 type strain of C. pneumoniae, which was also included in our panel. An MIC for grepafloxacin of 0.06 mg/L was obtained in both studies. However, our results are some two-to four-fold more active than those reported by Roblin et al.
11 against 12 isolates of C. pneumoniae, including TW183. They found grepafloxacin to be two-to four-fold more active than ofloxacin. Kenny & Cartwright 12 obtained results within the same range as ours for grepafloxacin and ofloxacin against M. pneumoniae, M. hominis and U. urealyticum, and our results for ofloxacin in the presents study are within the range previously reported by us. 13 We have reported previously good activity of the fluoroquinolones against Legionella spp., 13 and our results in this study confirm our previous results for ofloxacin and demonstrate equivalent activity for grepafloxacin. Gaja obtained similar results in an earlier study of 68 strains including representatives of all type species.
14 Preliminary reports on the pharmacokinetics of grepafloxacin by Childs et al. 6 indicate that peak serum levels of 1.5 mg/L are readily achieved after a single dose of 400 mg, and the drug persists above 0.5 mg/L for over 10-12 h. Further, the drug appears to penetrate tissues well. Legionellae and chlamydiae are intracellular organisms, and the mycoplasmas are cell associated. Thus, grepafloxacin may well have a role in the therapy of respiratory infections, particularly of the atypical pneumonia group, and also in the treatment of sexually transmitted disease. With regard to the latter, high activity against Neisseria gonorrhoeae has been reported, 5 underscoring an indication for clinical trials. The results will be awaited with interest. 
